Live Breaking News & Updates on Cosmetics Standard
Stay updated with breaking news from Cosmetics standard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article BOULDER, Colo., Jan. 28, 2021 /PRNewswire/ Synchronicity Full-Spectrum Hemp Oil announced today the successful completion of audits for ISO 9001:2015, an international quality management certification – excelling the company s current GMP certified manufacturing facility to a higher standard set by the FDA. Synchronicity is the first and only non-pharmaceutical hemp oil producer to earn this certification type across all business units - from growing and sourcing to bottling and distributing to consumers. This commitment to quality underscores Synchronicity s unique position in the marketplace by establishing trust with consumers. With over 3,500 CBD brands operating in the United States without FDA regulations for the production and packaging of dietary supplements or food containing CBD, there is no quality standard in the industry, leaving consumers and retail partners to determine on their own without parameters in place. ....
Search jobs 18-Jan-2021 Asia Pacific Alopecia Treatment Market Revenue to Worth Over US$ 3,214.8 Million by 2027, Owing to Increasing Clinical Trials in the Treatment of Alopecia Male or female pattern baldness, alopecia areata, telogen effluvium, and anagen effluvium are some of the types of alopecia. Topical alopecia drugs formulation are used in creams, oils, lotions, shampoos, foam forms that are intended to apply on the scalp in alopecia treatment. Asia Pacific US$ 4,060.9 Mn in terms of value and is expected to reach US$ 6,427.7 Mn by the end of 2027. Asia Pacific Alopecia Treatment Market: Drivers Increasing clinical trials in the treatment of alopecia is expected to propel growth of the Asia Pacific alopecia market over the forecast period. For instance, in June 2020, Concert Pharmaceuticals Inc. released new data analyses from its Phase 2 dose-ranging clinical trial of its inve ....